DasPAQT: Treating patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) with Dasatinib: PCR-Monitoring, adherence, quality of life, therapy satisfaction (OMC 2014-I; BMS CA180-565) - an analysis of the first 150 patients (2016) Tesch H, Pelz H, Janssen J, Hansen R, Fietz T, Anhuf J, Häberle L, et al. Conference contribution Response to 6 cycles of chemotherapy with FOLFIRINOX is predictive of overall survival in patients with locally advanced unresectable pancreatic cancer (2016) Haderlein M, Lubgan D, Lettmaier S, Semrau S, Wolf W, Golcher H, Hohenberger W, Fietkau R Conference contribution LOGIST - A local observational GIST registry: A non-interventional registry to observe patients with gastrointestinal stromal tumors (GIST) after R0/R1 resection - with or without adjuvant therapy with imatinib (CSTI571BDE77) - an interim analysis with 5 (2016) Reichardt P, Quietzsch D, Stuebs P, Cameron S, Gellert K, Wilhelm M, Killing B, et al. Conference contribution Factors Predicting Discordance in HER2 Phenotype between Primary Tumor and Circulating Tumor Cells in Women with Metastatic Breast Cancer (2016) Janni W, Schramm A, Friedl TWP, Schochter E, Huober J, Rack B, Alunni-Fabbroni M, et al. Conference contribution Effective long-term local results and prognostic factors after fractionated stereotactic radiotherapy of 257 intracranial meningeoma (2016) Lubgan D, Rutzner S, Semrau S, Lambrecht U, Roessler K, Buchfelder M, Fietkau R Conference contribution Cetuximab in combination with platinum-based chemotherapy or radiotherapy in recurent and/or metastatic SCCHN in a non-selected patient cohort (interim analysis of the phase IV SOCCER trial) (2016) Hecht M, Hahn D, Beutner D, Reichert D, Goehler T, Wurm R, Welslau M, et al. Conference contribution The DETECT Study Concept - Metastatic breast cancer and circulating tumor cells (2016) Schramm A, Friedl T, Rack B, Trapp E, Fasching P, Taran FA, Hartkopf A, et al. Conference contribution TREAT CTC: An innovative therapy approach to eliminate circulating tumor cells (CTCs) (2016) Tzschaschel M, Trapp E, Rack B, Messina C, Mueller V, Fehm T, Janni W, et al. Conference contribution Serum carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: a biomarker analysis from the GeparQuinto phase III neoadjuvant breast cancer trial (2016) Janning M, Mueller , Vettorazzi E, Cubas-Cordova M, Gensch , Ben Batalla , Eulenburg ZC, et al. Conference contribution Tumor infiltrating cells - cell-to-cell distances enable differentiation between functionally active and suppressed inflammatory cells (2016) Distel L, Nagl S, Fietkau R, Haas M Conference contribution